Samsung Biologics said Tuesday that it will participate in BioJapan 2025, Asia’s largest biotechnology and pharmaceutical exhibition, to be held in Yokohama, Japan, from Oct. 8 to 10.

Launched in 1986 by the Japan Bioindustry Association, BioJapan has grown into a flagship exhibition covering biopharmaceuticals, regenerative medicine, digital healthcare, and functional health foods. This year’s event is expected to attract more than 1,139 companies and 18,000 participants for business meetings and networking.

Samsung Biologics, joining the exhibition for the third consecutive year, will for the first time operate its own independent booth to actively pursue new contracts. The company said it aims to expand its share among the world’s top 20 pharmaceutical companies while accelerating new client acquisition in the top 40 tier.

The booth will highlight Samsung Biologics’ key strengths, including its antibody-drug conjugate (ADC) production capability, its fifth plant with 180,000 liters of capacity, and a total production scale of 784,000 liters -- the largest in the world.

The company will also spotlight its contract development (CDO) platform and integrated one-stop CDMO services, emphasizing the new dedicated ADC facility that began operations in March.

On Oct. 8, James Choi, Executive Vice President of Corporate Affairs, and Kevin Sharp, Executive Vice President of Sales and Operations, will deliver a joint presentation titled “Strategic Outsourcing for Supply Chain Resilience & Integrating Development and Manufacturing for Diverse Biologic Modalities.”

The session will outline the company’s strategies for supply chain stability and its comprehensive service offerings across biologic modalities.

Samsung Biologics has been stepping up its presence in Asia with the opening of a Tokyo office earlier this year, following its U.S. expansion.

In July, the company also participated in Interphex Week Tokyo 2025, another major pharmaceutical convention, to deepen engagement with global clients and reinforce its efforts to secure contracts among top 40 pharmaceutical companies.